Klein­er Perkins’ Beth Sei­den­berg bumps Tmu­ni­ty’s cell ther­a­py round to a cool $135M

Klein­er Perkins is join­ing the syn­di­cate back­ing Penn spin­out Tmu­ni­ty, adding $35 mil­lion for the cell ther­a­py cause and bring­ing its launch round to a mam­moth $135 mil­lion.

Gen­er­al Part­ner and long­time life sci­ences in­vestor Beth Sei­den­berg is han­dling the in­vest­ment for the high-pro­file ven­ture group. And she’s not at all new to this.

Sei­den­berg al­so in­vest­ed in Cell De­sign Labs, a com­pa­ny that was ad­vanc­ing a next-gen ap­proach to CAR-T un­der UCSF sci­en­tist Wen­dell Lim, which Gilead snapped up a few months ago in a deal worth up to $567 mil­lion in the wake of its $12 bil­lion Kite buy­out. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.